Delaying Diabetes Progression After Impaired Glucose Improves Long-Term Outcomes
By Lori Solomon HealthDay Reporter
WEDNESDAY, July 10, 2024 -- Maintaining several years of nondiabetes status after impaired glucose tolerance (IGT) diagnosis is associated with a significantly lower risk for poor long-term outcomes, according to a study published online July 9 in PLOS Medicine.
Xin Qian, from the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, and colleagues examined the association between years of nondiabetes status after diagnosis of IGT and the risk for long-term death and cardiovascular outcomes. The analysis included 540 individuals with IGT participating in the original Da Qing Diabetes Prevention Study who either maintained nondiabetes status or progressed to diabetes at the end of two, four, or six years after diagnosis of IGT.
The researchers found that the difference in the cumulative incidence rate of the outcomes between the diabetes and nondiabetes groups gradually increased over 30 years. There was a significantly lower risk for all-cause death (hazard ratio [HR], 0.74), cardiovascular events (HR, 0.63), and microvascular complications (HR, 0.62) observed in individuals who maintained nondiabetes status at the four-year visit compared with the diabetes group. A significant risk reduction in cardiovascular death was first seen at the end of six years (HR, 0.56), when adjusting for age, sex, smoking status, body mass index, systolic blood pressure, blood glucose, total cholesterol, intervention, and medications (including insulin plus oral hypoglycemics, antihypertensives, and lipid-lowering agents).
"The implementation of effective interventions targeting those with IGT should be considered as part of preventative management for diabetes and diabetes-related vascular complications," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-11 03:15
Read more
- Hourglass-Shaped Stent Might Ease Tough-to-Treat Angina
- Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
- UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
- American College of Allergy, Asthma & Immunology, Oct. 24-28
- Bird Flu Virus in Canadian Teen Shows Mutations That Could Help It Spread Among Humans
- Poll Finds Many Parents Struggling to Manage Kids' Anger
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions